Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. - Wikidata - awgldk - TriplyDB

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

http://www.wikidata.org/entity/Q42882364

about

Temozolomide for high grade glioma Recurrent Glioblastoma: Where we stand Biomarkers for glioma immunotherapy: the next generation International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors Controversies in the adjuvant therapy of high-grade gliomas.Salvage therapy with single agent bendamustine for recurrent glioblastoma."One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.Recurrent high-grade glioma: a diagnostic and therapeutic challenge.Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.The efficacy of temozolomide for recurrent glioblastoma multiforme.Surgical resection of malignant gliomas-role in optimizing patient outcome.Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway.Towards personalized therapy for patients with glioblastoma.The future of high-grade glioma: Where we are and where are we going.Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Dose-dense temozolomide: is it still promising?Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.Radiotherapy and temozolomide for anaplastic astrocytic gliomas.O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.Standards of care for treatment of recurrent glioblastoma--are we there yet?Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.Cell-based immunotherapy against gliomas: from bench to bedside Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).Evolving strategies: future treatment of glioblastoma.Current concepts and management of glioblastoma.Evolution of care for patients with relapsed glioblastoma.Temozolomide dosing regimens for glioma patients.State of the art and perspectives in the treatment of glioblastoma.Pharmacologic therapies for malignant glioma: a guide for clinicians.Treating recurrent glioblastoma: an update.Chemotherapy in glioma.Anaplastic glioma: current treatment and management.Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.Radiation therapy and grade II/III oligodendroglial tumors.

P2860

Q24197645-DAA42A65-91E3-452A-A4C0-3887702208E1 Q26765042-92E9CDF3-A701-44E7-B4B7-8DD6E8378820 Q26825496-2D1C0D12-B9ED-421D-85C7-9E6B59383FB6 Q30426724-0AE2A6F6-5584-452A-B30F-946569A096EC Q33394265-0CCF5C00-8276-4BBF-92D9-01F22D7441B1 Q33395579-52659876-F5EE-4F84-8829-3F263C0FA7AF Q33405170-734CABDF-E040-4F71-9781-959711443B75 Q33419628-7EAB461A-358E-4970-8C4A-7FB6807D81C7 Q33438666-7A1CE591-B5E4-4A73-B7BA-43E5429880A4 Q33864058-0961CBE2-032B-437F-A7CA-2D217669941E Q34186787-6BC04397-F690-4CE4-8967-6B65E6406DD9 Q34297519-9AC2DB4F-C68F-4586-9565-4872F230C8FE Q34324963-2F0DE93E-21D1-4109-9587-93B04C36D3E5 Q34500050-4CEE2FB9-5B34-4C0A-AFEC-40F67C8FC4FB Q34718233-55D15991-363B-45E2-B793-23107199EBF4 Q34978252-6E765C76-45F9-4132-8BF5-2544269E17AF Q35114090-9D0789D6-0C61-47BB-A717-9378FC4D9D6C Q35638372-D06CF68A-1ED1-4A22-AFFD-D26CA2A3F9B4 Q35676452-49CD1F17-299B-423A-8589-A10189256932 Q35943654-7CB5C25B-A031-4B97-8C4A-CE111B405ADE Q36096036-6304F43F-33DD-43D0-AD70-07B0B8E59F62 Q36163603-A69B6A5B-F888-49BB-A8E5-B4F4244462AF Q36288503-43DBE2B8-5CD7-436D-A9B0-6F43D6DA78CC Q36367414-926B19D2-556C-487A-BC48-BA9E2BE84ED8 Q36500401-E7A865F3-19FB-4881-A8C9-3C5E39CCEC17 Q36866006-4E2CDD59-309E-4011-81FD-63CC79B1622D Q36984482-22BC7826-F463-4C56-A834-DD5CBC025DD3 Q37278379-7846BBE4-E5D3-4E8E-930B-0D321C178CAC Q37369556-687ED652-C007-4F8E-913D-A83D06D32FFD Q37862235-F9553159-2DE6-4A37-BDDC-6356CD8A4622 Q37904921-6B7ED948-7A34-4259-89D5-B38BC523EB40 Q37952240-7419C34A-FFB2-4548-AA3A-D4BC99C32A1F Q37995906-3A493D73-07B4-41FA-A5DB-8785A527783F Q38233067-D698DA58-7287-49C1-A83F-C697BFE583E8 Q38268897-0B14DDCC-27ED-4C8F-91A0-241AF2D4C230 Q38376610-A4C58AB7-74D6-4757-A19A-5EEDBB413F98 Q38438439-78CB1E7E-B21E-483C-BCD5-0CD7B270D612 Q38456018-52D0A0CC-44E1-4FC2-BBFE-CBC755D62341 Q38602651-220812F7-A32C-4155-9B29-AC56C5F2506E Q38610442-B3FA377A-9A13-4170-BFC7-1E61201F8741

P2860

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

http://www.wikidata.org/entity/Q42882364

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Temozolomide versus procarbazi ...... n recurrent high-grade glioma.

@en

Temozolomide versus procarbazi ...... n recurrent high-grade glioma.

@nl

type

label

Temozolomide versus procarbazi ...... n recurrent high-grade glioma.

@en

Temozolomide versus procarbazi ...... n recurrent high-grade glioma.

@nl

prefLabel

Temozolomide versus procarbazi ...... n recurrent high-grade glioma.

@en

Temozolomide versus procarbazi ...... n recurrent high-grade glioma.

@nl

P1433

Q42882364-BE6F3098-C755-4832-835A-76C9E6FF3BE6

P1476

Q42882364-7C68C1B0-2567-4962-B0AB-E0B5DEC8CF84

P2093

Q42882364-11793C4E-61E3-46AE-827A-A7389523C653

Q42882364-199830B1-DF69-4042-8415-76F9CEEA34FD

Q42882364-1CEC3D69-0514-47E8-BFC0-0D94DEA5D401

Q42882364-22067F53-ECF4-4CAC-B617-CA8B7B9B9654

Q42882364-40C22F6F-FF06-47DC-98ED-549D73D3503B

Q42882364-55D4DD8F-F09E-4E2B-8473-D2E1DF00782F

Q42882364-AAFCCEA2-CEBA-4FEE-AA57-172407D5A45F

Q42882364-ADC48399-9537-424D-A108-35FE0AF89256

Q42882364-B330CC15-0A60-4B47-93A7-C3339AAE4F57

Q42882364-E5540328-82EE-478F-8477-AAC89E35A1A7

P304

Q42882364-F2018720-5468-468C-B498-5626F877D061

P31

Q42882364-9B96BC09-E197-4817-8C05-34825A4EAEA5

P356

Q42882364-7A41F2C5-CE23-447A-AFE0-79BE5EB590CD

P407

Q42882364-C7754CC8-8012-4DE5-BBB2-97028D6E41C1

P433

Q42882364-D38AAF88-DCC3-43CE-B6BB-1F46D70CA2C8

P478

Q42882364-CA1A5413-782B-45B9-823D-823826373366

P50

Q42882364-626A38E1-D83D-4AA8-AF34-48E16C98C77A

Q42882364-A28573DF-24E2-4371-8E07-06CA1B16AF6A

P577

Q42882364-240213F0-F5A7-408E-ACF2-601FCDA514A6

P698

Q42882364-1163219D-77A6-42C9-8912-010F65619D2B

P356

JCO.2009.27.1932

P1433

Journal of Clinical Oncology

P1476

Temozolomide versus procarbazi ...... in recurrent high-grade glioma

@en

P2093

David Levy

http://www.w3.org/2001/XMLSchema#string

Frank Saran

http://www.w3.org/2001/XMLSchema#string

Kirsten Hopkins

http://www.w3.org/2001/XMLSchema#string

Lindsay C Thompson

http://www.w3.org/2001/XMLSchema#string

Michael Brada

http://www.w3.org/2001/XMLSchema#string

Rao Gattamaneni

http://www.w3.org/2001/XMLSchema#string

Roy Rampling

http://www.w3.org/2001/XMLSchema#string

Sally Stenning

http://www.w3.org/2001/XMLSchema#string

Sara Erridge

http://www.w3.org/2001/XMLSchema#string

Sarah Beall

http://www.w3.org/2001/XMLSchema#string

P304

4601-4608

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.27.1932

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20855843

http://www.w3.org/2001/XMLSchema#string